@i2.lyrics: Part : 1 makul kaderime yok tessli,,follow ♥️ #tiktok #foryoupage #fyp #turkey #song

.

Open In TikTok:

Region: IQ

Sunday 20 September 2026 10:26:25 GMT

121998

11109

42

363

Music

Download

No Watermark .mp4 (1.23MB) No Watermark(HD) .mp4 (2.14MB) Watermark .mp4 (2.23MB) Music .mp3

Comments

selenbllc67 :

Ziyankar!!

2026-09-22 15:38:23

59

AM⏳ :

Abbem.[Exclaim heart]

2026-09-25 21:13:43

0

Rimah Ghomari :

altı üstü İstanbul

2026-09-22 19:16:53

10

﮼ود❤️. :

2026-09-21 18:31:35

28

𝑶𝑺𝑯𝑨❣️ :

2026-09-26 13:36:46

1

🪼. :

Ah bayıldım

2026-09-24 16:58:34

5

samia :

2026-09-23 20:41:40

6

كــرار :

2026-09-24 20:57:22

5

𝑆 𝐽𝑘 𝑇𝑘 𝐴❣️🙈 :

2026-09-23 13:59:28

9

🤍TASSNIM🤍 :

2026-09-22 18:21:23

8

🥀 :

2026-09-22 14:33:50

8

zeynalovv_50 :

🤩🤩

2026-09-22 18:09:12

9

N :

2026-09-22 11:18:47

6

愛 :

2026-09-21 21:53:42

6

rrah.13 :

2026-09-22 15:13:40

5

Hamza Zara :

2026-09-21 19:42:19

8

ba_ll_rinaa__ :

2026-09-22 19:40:58

5

I_𝐚𝐛𝐝𝐮𝐥𝐨𝐯𝐚🐾 :

2026-09-22 18:05:44

7

en büyük ramos fanı :

2026-09-24 11:55:01

4

T :

2026-09-22 19:41:46

4

𝓜𝓮𝓵𝓲x🇮🇹 :

2026-09-23 17:57:08

4

Éssou🦢 :

2026-09-22 19:26:58

1

Retal :

2026-09-24 21:13:30

0

Retal :

2026-09-24 21:13:26

0

𝓔𝓼𝓵𝓮𝓶 :

2026-09-24 13:06:45

0

To see more videos from user @i2.lyrics, please go to the Tikwm homepage.

Other Videos

Scramble up ur name & I’ll try to guess it😍❤️ #foryoupage #PetsOfTikTok #aesthetic

Scramble up ur name & I’ll try to guess it😍❤️ #foryoupage #PetsOfTikTok #aesthetic

FOLLOW sasa hivi — kesho unaweza kuitafuta page hii usiione #techtake #LetsDoThis #fyp #fyppppppppppppppppppppppp

FOLLOW sasa hivi — kesho unaweza kuitafuta page hii usiione #techtake #LetsDoThis #fyp #fyppppppppppppppppppppppp

#police #cops #law #copsoftiktok #fyp

#police #cops #law #copsoftiktok #fyp

My cat turned into a jinn 💔 #horroranimal #viral #GHOST #horror #fypppppppppppppp

My cat turned into a jinn 💔 #horroranimal #viral #GHOST #horror #fypppppppppppppp

Headline Hype vs. Clinical Reality When headlines use words like “terrifying” around GLP-1s, it’s normal to feel concerned. Looking past clickbait to understand real-world clinical math helps you make confident, empowered health decisions. 1. Relative vs. Absolute Risk News outlets love relative risk because big multipliers drive clicks. Relative Risk: If a rare condition goes from 1 in 10,000 to 2 in 10,000, headlines scream

Headline Hype vs. Clinical Reality When headlines use words like “terrifying” around GLP-1s, it’s normal to feel concerned. Looking past clickbait to understand real-world clinical math helps you make confident, empowered health decisions. 1. Relative vs. Absolute Risk News outlets love relative risk because big multipliers drive clicks. Relative Risk: If a rare condition goes from 1 in 10,000 to 2 in 10,000, headlines scream "100% RISK INCREASE!" Absolute Risk: Your real-world chance only changed by 0.01% (from 0.01% to 0.02%). 2. The Vision Loss Risk (NAION) The Math: Multi-year registry data shows the cumulative absolute risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) for GLP-1 users remains low, at 3 to 4 cases per 10,000 people (<0.04%). Clinical Consensus: The AAO and NANOS joint consensus confirms that while a modest relative association exists (~2-fold), direct causality is unproven. ****Always monitor for visual changes and consult your provider. 3. The Unsung Benefit: Cancer Reduction Scary headlines ignore major positive clinical data (JAMA Oncology, JAMA Network Open). GLP-1s lower obesity-associated cancer risks across both relative and absolute metrics: Overall Cancer: An absolute drop of 2.8 fewer cases/1,000 people/year (drops from 16.4 to 13.6 per 1,000 person-years — a 17% relative reduction). Endometrial Cancer: An absolute drop of ~0.4 fewer cases/1,000 person-years (a 25% relative reduction). Ovarian Cancer: An absolute drop of ~0.2 fewer cases/1,000 person-years (a 47% relative reduction). Colorectal Cancer: An absolute drop of ~0.5–1 fewer cases/1,000 person-years (up to a 28% relative reduction). By improving metabolic health, lowering fasting insulin, and calming systemic inflammation, GLP-1s address root drivers of cellular damage. Educational Only. Not Medical Advice. It is still important to monitor for any visual changes, research any medication or supplement you take, and discuss any concerns directly with your provider. Silence Medical PLLC | Evidence-based metabolic care focused on muscle preservation. 📲 Telemedicine in AZ, CO, & OR | www.silencemed.com References Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):731–739. doi:10.1001/jamaophthalmol.2024.2296 Grauslund J, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy. Acta Ophthalmol. Published online 2024. PMID: 39696569. DeParis S, Oke I, Gaier E, et al. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. Published online August 2026. Biousse V. Consensus Statement Shows a Possible Small Association Between GLP-1 RA Drugs and NAION. American Academy of Ophthalmology (AAO) Editor's Choice. Published August 27, 2026. Dai H, Li Y, Lee Y, et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025;11(10):e252681. doi:10.1001/jamaoncol.2025.2681 Wang L, Xu R, Kaelber DC, Berger NA. GLP-1 Receptor Agonists and Risk of Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024;7(7):e2421305. doi:10.1001/jamanetworkopen.2024.21305 #GLP1 #WeightLossJourney #Telehealth #SilenceMedical #Semaglutide

#audit #fouyou #policeofficer #fyp #copsoftiktok #1st #1stamendment

#audit #fouyou #policeofficer #fyp #copsoftiktok #1st #1stamendment

About

Robot
API

Legal

Privacy Policy